Liu Zhi-Qiang, Wang Li
Department of Nephrology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China.
Di Yi Jun Yi Da Xue Xue Bao. 2002 Oct;22(10):942-3.
To compare the anticoagulation efficacy and clinical safety of domestically manufactured and imported low-molecular-weight-heparin during hemodialysis.
Sixty patients on hemodialysis were randomly divided into 2 groups, who received intravascular injections of domestically manufactured or imported low-molecular-weight heparin to prevent coagulation. Active partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT) and factor Xa activity were determined during dialysis.
No incidence of major bleeding was encountered in all of these patients. Similarly low incidences of clotting in extracorporeal circuit were found in either group. No significant differences in aPTT, PT, TT and plasma levels of factor Xa were observed between the two groups.
Low-molecular-weight heparin domestically manufactured is safe and efficient for anticoagulation during hemodialysis as compared with the imported heparin.
比较国产与进口低分子肝素在血液透析过程中的抗凝疗效及临床安全性。
将60例血液透析患者随机分为2组，分别接受国产或进口低分子肝素血管内注射以预防凝血。透析过程中测定活化部分凝血活酶时间（aPTT）、凝血酶原时间（PT）、凝血酶时间（TT）及Xa因子活性。
所有患者均未发生大出血事件。两组体外循环凝血发生率同样较低。两组间aPTT、PT、TT及血浆Xa因子水平未见显著差异。
与进口肝素相比，国产低分子肝素在血液透析过程中抗凝安全有效。
